Astemizole

CAS No:
68844-77-9 Category:
  • #LGM Pharma is a Astemizole CAS# 68844-77-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 68844-77-9
  • AHFC code:
  • Synonyms:
  • ATC Code: R06AX11
  • Chemical Formula: C22H29FO5
  • Molecular Weight: 458.5703
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00637 (APRD00585)
  • SMILES: COC1=CC=C(CCN2CCC(CC2)NC2=NC3=CC=CC=C3N2CC2=CC=C(F)C=C2)C=C1
  • InChl: GXDALQBWZGODGZ-UHFFFAOYSA-N
  • PubChem: 2247
  • IUPAC: 1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-1,3-benzodiazol-2-amine

Additional Details

Indication:
Astemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
Pharmacodynamics:
Astemizole is a second generation H1-receptor antagonist. It does not significantly cross the blood brain barrier and therefore does not cause drowsiness or CNS depression at normal doses.
Mode of Action:
Astemizole competes with histamine for binding at H_-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. This reversible binding of astemizole to H_-receptors suppresses the formation of edema, flare, and pruritus resulting from histaminic activity. As the drug does not readily cross the blood-brain barrier and preferentially binds at H_ receptors in the peripehery rather than within the brain, CNS depression is minimal. Astemizole may also act on H_-receptors, producing adverse effects.
Metabolism:
Almost completely metabolized in the liver and primarily excreted in the feces.
Toxicity:
LD50=2052mg/kg in mice
General Reference:
Wang X, Hockerman GH, Green HW 3rd, Babbs CF, Mohammad SI, Gerrard D, Latour MA, London B, Hannon KM, Pond AL: Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway. FASEB J. 2006 Jul;20(9):1531-3. Epub 2006 May 24. Pubmed Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ Jr: A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006 Aug;2(8):415-6. Epub 2006 Jul 2. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos